Myelodysplastic Syndromes Foundation is ranked #41 of 51 disease & disorders organizations in New York, NY, with an America's Best Score of 65 out of 100, based on its 2025 Form 990.
Myelodysplastic Syndromes Foundation is a 501(c)(3) organization, classified under Disease & Disorders (NTEE G30). Contributions are tax-deductible.
228 Park Ave S Pmb 118983, New York, NY 10003-0103
Among the 85 scored disease & disorders organizations in New York, Myelodysplastic Syndromes Foundation holds 9.6 months of operating reserves (peer median 11.2 months), runs a typical yearly deficit of 27.4% (peers: surplus of 0.8%), and has grown spending 11.8% a year (peers: grown spending 6.1% a year).
In fiscal year 2025 it reported $1,859,509 in revenue and $3,034,024 in expenses, with contributions making up 98.3% of revenue.
The mds foundation is a global nonprofit dedicated to improving the lives of patients with myelodysplastic syndromes (mds) through patient support, education, advocacy, research, and collaboration to advance better care and outcomes worldwide.
Largest programs · fiscal year 2025
The mds foundation advocates on behalf of individuals affected by myelodysplastic syndromes (mds), a rare and complex blood cancer. Through education, awareness, and patient engagement, we empower patients and caregivers to make informed healthcare decisions and access appropriate care.we work with healthcare professionals, researchers, and industry stakeholders to ensure the patient voice is repr… Read more
The mds foundation advocates on behalf of individuals affected by myelodysplastic syndromes (mds), a rare and complex blood cancer. Through education, awareness, and patient engagement, we empower patients and caregivers to make informed healthcare decisions and access appropriate care.we work with healthcare professionals, researchers, and industry stakeholders to ensure the patient voice is represented in treatment development, policy discussions, and clinical guidelines. We provide multilingual educational materials, patient navigation services, public awareness campaigns, and referrals to mds centers of excellence around the world.
$1,464,845 spent · 71.4% of program spending
Educational symposia and a bi-annual conference are conducted in partnership with several societies and associations, including the American society of hematology and the oncology nursing society. In addition, the foundation hosts its own professional educational programs designed to advance the understanding of myelodysplastic syndromes (mds), improve the quality of patient care, and support the… Read more
Educational symposia and a bi-annual conference are conducted in partnership with several societies and associations, including the American society of hematology and the oncology nursing society. In addition, the foundation hosts its own professional educational programs designed to advance the understanding of myelodysplastic syndromes (mds), improve the quality of patient care, and support the continuing education of healthcare professionals. These informative and interactive programs are aimed at hematologists, oncology nurses, hematology fellows, pharmacists working with mds patients, and other allied health professionals involved in the care and treatment of individuals with mds.
$269,674 spent · 13.1% of program spending
The mds foundation supports and advances scientific research in myelodysplastic syndromes (mds) through its young investigator research program. The foundation invites early-career investigators to submit proposals focused on basic science or clinical research related to the causes, epidemiology, molecular biology, cytogenetics, morphology, prognosis, and management of mds.in addition to funding i… Read more
The mds foundation supports and advances scientific research in myelodysplastic syndromes (mds) through its young investigator research program. The foundation invites early-career investigators to submit proposals focused on basic science or clinical research related to the causes, epidemiology, molecular biology, cytogenetics, morphology, prognosis, and management of mds.in addition to funding individual research, the foundation convenes international working groups composed of leading scientists and physicians to collaboratively improve diagnostic standards, prognostic tools, and treatment strategies.
$316,650 spent · 15.4% of program spending
Where each dollar went · fiscal year 2025
Of every dollar it spent, 68¢ went to programs, 15¢ to management and 17¢ to fundraising.
Programs $2,051,169
Management $453,393
Fundraising $529,462
In the organization's own words to the IRS, shown for context. None of this affects the America's Best Score, and a Form 990 describes programs without measuring their results.
Spending on programs Not scored; America's Best needs 65%+
68%
Meets
Compared with New York peers
Measure
This organization
Peer median
Operating reserves
9.6 mo
11.2 mo
Typical margin
−27.4%
+0.8%
Spending growth
+11.8% / yr
+6.1% / yr
Debt load
8.0%
7.4%
Peers: the 85 New York disease & disorders organizations with a score, ranked or below the bar.
Tax filings by year
Financial data extracted from the Form 990 the organization filed with the IRS for each fiscal year. Revenue lines can exceed 100% when other items, such as fundraising event costs, are netted against total revenue.
Revenue$1,859,509Fiscal year 2025
Expenses$3,034,024Fiscal year 2025
Total assets$2,623,801Fiscal year 2025
Total liabilities$208,943Fiscal year 2025
Fiscal year ending December2025
Revenue$1,859,509
Expenses$3,034,024
Net income−$1,174,515
Net assets$2,414,858
Notable sources of revenue
Percent of total revenue
Contributions
$1,828,816
98.3%
Program services
$0
0.0%
Investment income
$27,075
1.5%
Other (net)
$3,618
0.2%
Assets / debt
Total assets
$2,623,801
Total liabilities
$208,943
Net assets
$2,414,858
Compensation
Not in our extract for this year.
Fiscal year ending December2024
Revenue$2,002,126
Expenses$2,953,868
Net income−$951,742
Net assets$3,589,373
Notable sources of revenue
Percent of total revenue
Contributions
$1,948,899
97.3%
Program services
$0
0.0%
Investment income
$3,563
0.2%
Other (net)
$49,664
2.5%
Assets / debt
Total assets
$3,847,112
Total liabilities
$257,739
Net assets
$3,589,373
Compensation
Not in our extract for this year.
Fiscal year ending December2023
Revenue$2,562,806
Expenses$3,312,848
Net income−$750,042
Net assets$4,391,725
Notable sources of revenue
Percent of total revenue
Contributions
$1,558,359
60.8%
Program services
$972,104
37.9%
Investment income
$32,321
1.3%
Other (net)
$22
0.0%
Assets / debt
Total assets
$5,146,339
Total liabilities
$754,614
Net assets
$4,391,725
Compensation
Not in our extract for this year.
Fiscal year ending December2022
Revenue$2,521,375
Expenses$2,174,159
Net income$347,216
Net assets$5,140,891
Notable sources of revenue
Percent of total revenue
Contributions
$2,618,926
103.9%
Program services
$405,541
16.1%
Investment income
$8,487
0.3%
Other (net)
−$511,579
−20.3%
Assets / debt
Total assets
$5,422,226
Total liabilities
$281,335
Net assets
$5,140,891
Compensation
Officers and key employees
$147,110
Share of expenses
6.8%
Fiscal year ending December2021
Revenue$4,660,616
Expenses$2,815,786
Net income$1,844,830
Net assets$4,792,599
Notable sources of revenue
Percent of total revenue
Contributions
$3,830,988
82.2%
Program services
$1,076,737
23.1%
Investment income
$2,252
0.0%
Other (net)
−$249,361
−5.4%
Assets / debt
Total assets
$5,238,327
Total liabilities
$445,728
Net assets
$4,792,599
Compensation
Officers and key employees
$198,251
Share of expenses
7.0%
About this data
Figures come from IRS Form 990 filings, through the IRS Exempt Organizations Business Master File (2026-11-09) and e-filed returns. Form 990 data typically lags 12–24 months behind an organization's fiscal year. Found an error?